Menu
Lab 2 Market program enabled critical evaluation and testing of commercial potential for our DarwinAI platform.
NuvoBio was granted a patent for KDM5C targeting peptide. One of the very firts peptides to come out of DarwinAI.
NuvoBio graduates as part of the CDL Advanced Therapies stream. Supported by angel investors, economists, and scientists.
Capital BioVentures supports NuvoBio through non-dilutive funding with access to experts-in-residence program. Read more!
A Patent Cooperation Treaty (PCT) submitted for the NeoPeptix peptide that works by inhibiting Cryptococcus neoformans.
NuvoBio is one of the first companies to receive lab space and funding through the Capital BioVentures program!
Submitted an application to patent our peptide discovery platform that powers the work we do here at NuvoBio.
A talented team of experienced researchers and business development experts support us through the Capital BioVentures experts-in-residence program.
Reach out to us to learn more about how our talented team of experts can accelerate your drug discovery process using our cuting edge platform.